Amyloid-β Clearance Mechanisms in Alzheimer's Disease

Who May Qualify: - Diagnosis of amnestic MCI or AD dementia or clinical normal - Able to provide written willing to sign a consent form - Unchanged pharmacotherapy within 4 days prior to the study specific assessments - Fluent in German Who Should NOT Join This Trial: - Unable to give willing to sign a consent form or has a legal guardian - Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder - Clinically relevant depression - Acute suicidality - Current alcohol, drug or medication abuse - History of severe traumatic brain injury within 3 months prior to inclusion - Structural lesions of the basal ganglia or brain stem - Severe neurological disorder including (but not limited to) epilepsy, systemic disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial pressure, normal pressure hydrocephalus - Severe medical disorders including (but not limited to) heart failure, respiratory failure, uncontrolled severe arterial hypertension - Electronic implants (e.g. cardiac pacemaker) or other MRI contraindication - Renal failure \> stage 3 (GFR \< 30 mL/min) - Pregnancy - Unresolved malignancies within two years prior to inclusion - Severe current infections or other chronic or systemic disorders - Other circumstances which preclude participation based on the investigator's judgement Always talk to your doctor about whether this trial is right for you.